May 17, 2012 Cynapsus Therapeutics Retains US Investor Relations Firm Read More >		May 3, 2012 Cynapsus Therapeutics Nominates New Directors for Board Read More >
		April 23, 2012 Cynapsus Therapeutics appoints Dr. Abraham Lieberman to Clinical Advisory Board Read More >		April 16, 2012 Cynapsus Provides Update and 2012 Outlook Read More >
		March 26, 2012 Cynapsus Therapeutics Reports 2011 Financial Results and Highlights Key Developments Read More >		March 9, 2012 Cynapsus Therapeutics Announces $1 Million Financing Read More >
				Press Release Archive

Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease. Over one million people in the United States and an estimated 5 million people globally suffer from Parkinson's disease. Parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population.